Beschreibung
TB500 is a synthetic version of an active region of thymosin β4. TB500 exhibits anti-fibrotic and wound healing activities by inhibiting the Akt signaling pathway and binding to actin. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation[1][2][3]. In Vitro
TB500 exhibits tissue repairing and regenerative activities through its active ingredient Ac-Tβ417-23. Ac-Tβ417-23 prevents apoptosis, promotes cell survival and angiogenesis, stimulates T cell proliferation, exhibiting immunomodulatory activity[2]. TB500 (15-25 μg/mL, 2 days) promotes cell migration and wound healing by enhancing ATP-induced increase in intracellular calcium ions and activating purinergic P2 receptors[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Migration Assay [3]
Cell Line: PAM212 Concentration: 15-25 μg/mL Incubation Time: 2 days Result: Promoted cell migration. In Vivo
TB500 (10 mg/dose, single dose) can be used as doping agent in horse and greyhound racing[2]. TB500 (15 μg/30 μL, topical administration, once daily for 10 days) promotes wound healing, and exhibits good tissue repair effects in BALB/c mouse models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: BALB/c mouse skin wound models[3] Dosage: 15 μg/30 μL Administration: 15 μg/30 μL, topical administration, once daily for 10 days Result: Accelerated wound healing. Klinische Studie
Molekulargewicht
889.01 Formel
C38H68N10O14 CAS. Nr.
885340-08-9 Appearance
Solid Color
White to off-white Sequence
N-Acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln Sequence Shortening
Ac-LKKTETQ Versand
Room temperature in continental US; may vary elsewhere. Speicherung
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year Lösungsmittel & Löslichkeit
In Vitro:
H2O : ≥ 200 mg/mL (224.97 mM)
*"≥" means soluble, but saturation unknown.
Preparing Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.1248 mL 5.6242 mL 11.2485 mL 5 mM 0.2250 mL 1.1248 mL 2.2497 mL
View the Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Molaritätsrechner
Verdünnungsrechner
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Mass
= Concentration
× Volume
× Molecular Weight *
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 Concentration (start)
C1
× Volume (start)
V1
= Concentration (final)
C2
× Volume (final)
V2
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage
mg/kg
Animal weight (per animal)
g
Dosing volume (per animal)
μL
Number of animals
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE). Reinheit & Dokumentation
Purity: 99.57%
Select Batch:
SDS (252 KB)
COA (249 KB) RP-HPLC (266 KB) LCMS (95 KB) Elemental Analysis Report (108 KB)
Handling Instructions (2659 KB) Verweise
[1]. Emmie N M Ho, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 Nov 23;1265:57-69. [Content Brief]
[2]. Esposito S, et al., Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012 Sep;4(9):733-8. [Content Brief]
[3]. Huang CM, et al., In vivo detection of secreted proteins from wounded skin using capillary ultrafiltration probes and mass spectrometric proteomics. Proteomics. 2006 Nov;6(21):5805-14. [Content Brief]
[4]. Shah R, et al., Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opin Biol Ther. 2018 Jul;18(sup1):177-184. [Content Brief]